1365267-33-9
1365267-33-9
Chemical Structure
Codrituzumab
Synonym(s): GC33; RO5137382
- CAS No.: 1365267-33-9
- Formula:N/A
- Molecular Weight:(145.58 kDa)
IUPAC Name: sodium 1,4-bis((2-(ethyl-d5)hexyl-1,1,2,3,3,4,4,5,5,6,6,6-d12)oxy)-1,4-dioxobutane-2-sulfonate
SMILES: [Codrituzumab]
Biological Activity: Codrituzumab (GC33) is a humanized monoclonal antibody targeting human GPC3 (glypican-3), with high affinity (Kd of 0.673 nM). GPC3 is an oncofetal protein expressed on the cell surface of hepatocellular carcinoma (HCC). Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Codrituzumab | 99.07% | Codrituzumab (GC33) is a humanized monoclonal antibody targeting human GPC3 (glypican-3), with high affinity (Kd of 0.673 nM). GPC3 is an oncofetal protein expressed on the cell surface of hepatocellular carcinoma (HCC). Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Mika Endo, et al. Abstract 2747: Anti-glypican-3 monoclonal antibody (codrituzumab/GC33/RO5137382) treatment enhances tumor infiltration of PD-L1-positive macrophages, and combination therapy with anti-PD-L1 monoclonal antibody promotes antitumor effects. Cancer Res (2018) 78 (13_Supplement): 2747.
- [2]. Chen G, et al. Combining expression of GPC3 in tumors and CD16 on NK cells from peripheral blood to identify patients responding to codrituzumab. Oncotarget. 2018 Jan 2;9(12):10436-10444. [Content Brief]
- [3]. Carrasquillo JA, et al. I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma. EJNMMI Res. 2018 Mar 5;8(1):20. [Content Brief]
- [4]. Abou-Alfa GK, et al. Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma. J Hepatol. 2016 Aug;65(2):289-95. [Content Brief]
Keywords
